**Advances and challenges in the treatment of castration resistant prostate cancer**

**Poster Session 64**

**Monday 18 March**

**12:15 - 13:45**

**Location:** Green Area, Room 4

**Chairs:**
- R. Azhar, Jeddah (SA)
- R.J. Van Soest, Rotterdam (NL)
- A. Zarkar, Birmingham (GB)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

---

**Risk of dementia following androgen deprivation therapy for treatment of prostate cancer**

By: Tully K.¹, Krasnova A.², Epstein M.³, Marchese M.¹, Dickerman B.⁴, Cole A.P.¹, Lipsitz S.⁵, Nguyen P.⁶, Kibel A.¹, Choueiri T.⁷, Basaria S.⁸, Mucci L.⁴, Sun M.⁷, Trinh Q-D.¹

¹Brigham and Women's Hospital, Harvard Medical School, Division of Urologic Surgery and Center for Surgery and Public Health, Boston, United States of America, ²Columbia Mailman School of Public Health, Columbia Mailman School of Public Health, New York, United States of America, ³SUNY Downstate Medical Center, SUNY Downstate Medical Center, Boston, United States of America, ⁴Harvard TH Chan School of Public Health, Dept. of Epidemiology, Boston, United States of America, ⁵Brigham and Women's Hospital, Harvard Medical School, Division of General Internal Medicine and Center for Surgery and Public Health, Boston, United States of America, ⁶Brigham and Women's Hospital, Harvard Medical School, Dept. of Radiation Oncology, Boston, United States of America, ⁷Dana Farber Cancer Institute, Harvard Medical School, Lank Center for Genitourinary Oncology, Boston, United States of America, ⁸Brigham and Women's Hospital, Harvard Medical School, Research Program in Men's Health: Aging and Metabolism, Boston, United States of America

**Aims and objectives of this presentation**

---

**Radium 223 therapy in symptomatic metastatic castrate resistant prostate cancer - quality of life matters: Real-world outcomes from a single UK centre**

By: Jiang X.Y.¹, Atkinson S.², Cumming S.¹, Burns A.³, Pearson R.A.¹, Frew J.¹, Azzabi A.¹, McMenemy R.¹, Pedley I.¹

¹Northern Centre for Cancer Care, Dept. of Clinical Oncology, Newcastle upon Tyne, United Kingdom, ²Northern Centre for Cancer Care, Dept. of Nuclear Medicine, Newcastle upon Tyne, United Kingdom, ³Northern Centre for Cancer Care, Dept. of Radiotherapy Information Technology, Newcastle upon Tyne, United Kingdom
Withdrawn
To be confirmed

Aims and objectives of this presentation

Disease burden and bone health in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO non-interventional study

By: Poeppel T.D. 1, Möllers M. 2, Assa E. 3, Kalinovsky J. 4, Benson A. 5, Selkinski I. 3
1University of Duisburg-Essen and German Cancer Consortium (DKTK), partner site University Hospital Essen, Dept. of Nuclear Medicine, Essen, Germany,
2Knappschaftskrankenhaus Dortmund, Dept. of Nuclear Medicine, Dortmund, Germany,
3Helios Dr. Horst-Schmidt-Kliniken, Institute of Nuclear Medicine, Wiesbaden, Germany,
4Bayer Consumer Care AG, Medical Affairs – Oncology, Basel, Switzerland,
5Bayer HealthCare, Medical Affairs – Statistics, Whippany, United States of America

Aims and objectives of this presentation

Overall adverse events in patients treated with radium223 for metastatic castration resistant prostate cancer: Registry study and analysis of real life data from EudraVigilance

Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation

Circulating tumour cells in patients with metastatic castration resistant prostate cancer under treatment with cabazitaxel - a prospective biomarker study from the Hellenic Oncology Research Group

Hellenic Oncology Research Group, Dept. of Medical Oncology, Athens, Greece

Aims and objectives of this presentation

Next generation sequencing (NGS) in metastatic castration resistant prostate cancer (mCRPC) to identify targets for individualized treatment – is it feasible in daily routine?

By: Heidenreich A. 1, Nestler T. 1, Paffenholz P. 1, Büttner R. 1, Karapanos L. 2, Pfister D. 1
### Aims and objectives of this presentation

**Comparison of docetaxel and androgen receptor axis-targeted (ARAT) agents for metastatic castration-resistant prostate cancer patients with intraductal carcinoma of the prostate (IDC-P)**

By: Kato M.\(^1\), Yamamoto A.\(^2\), Tochigi K.\(^1\), Ohwaki T.\(^1\), Ishida S.\(^3\), Fujita T.\(^1\), Sassa N.\(^1\), Gotoh M.\(^1\), Tsuzuki T.\(^3\)

\(^1\)Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan,
\(^2\)Toyohashi Municipal Hospital, Dept. of Urology, Toyohashi, Japan,
\(^3\)Aichi Medical University, School of Medicine, Dept. of Surgical Pathology, Nagakute, Japan

### Aims and objectives of this presentation

**Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Long-term overall survival and safety analyses of the phase 3 PREVAIL study**

By: Armstrong A.\(^1\), Tombal B.\(^2\), Saad F.\(^3\), Parli T.\(^4\), Phung D.\(^5\), Beer T.M.\(^6\)

\(^1\)Duke University, Dept. of Medicine and Surgery, Durham, United States of America,
\(^2\)Clinique Universitaires Saint-Luc, Dept. of Urology, Brussels, Belgium,
\(^3\)University of Montreal Hospital Center, Dept. of Urologic Oncology, Montreal, Canada,
\(^4\)Pfizer Inc., Clinical Development, San Francisco, United States of America,
\(^5\)Astellas Pharma Inc., Dept. of Biostatistics, Leiden, The Netherlands,
\(^6\)OHSU Knight Cancer Institute, Oregon Health & Science University, Dept. of Hematology-Medical Oncology, Portland, United States of America

### Aims and objectives of this presentation

**Performance of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer men: A head to head comparison based on a 2014-2017 French population-based study**

By: Scailteux L. M.\(^1\), Campillo-Gimenez B.\(^2\), Kerbrat S.\(^3\), Despas F.\(^4\), Mathieu R.\(^5\), Vincendeau S.\(^5\), Balusson F.\(^3\), Happe A.\(^3\), Nowak E.\(^6\), Oger E.\(^3\)

\(^1\)CHU Rennes, Dept. of Pharmacovigilance and pharmacoepidemiology, Rennes, France,
\(^2\)INSERM, U1099, Centre Eugène Marquis, Promotion of Clinical Trials, Rennes, France,
\(^3\)Université de Rennes, Dept. of Pharmacoeconomics and Health Services Research, Rennes, France,
\(^4\)University Hospital of Rangueil Toulouse, Inserm U1048, Toulouse, France,
\(^5\)CHU Rennes, Dept. of Urology, Rennes, France,
\(^6\)Université de Bretagne Loire, Université de Brest, CHRU de Brest, INSERM CIC 1412, Brest, France
Aims and objectives of this presentation
901

Open-label, phase I, dose escalation study to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E (GEN0101) in castration-resistant prostate cancer patients


Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Japan,

Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan,

Osaka University Graduate School of Medicine, Division of Gene Therapy Science, Suita, Japan

Aims and objectives of this presentation
902

Age influence on adverse events in patients treated with abiraterone plus prednisone, enzalutamide and radium-223 for metastatic castration resistant prostate cancer: Analysis of real life data from Eudra Vigilance database.


Sapienza University of Rome, Sant'Andrea Hospital, Dept. of Urology, Rome, Italy

Aims and objectives of this presentation
903

Late administration of luteinizing hormone-releasing hormone agonists, the impact on testosterone (T) suppression, and frequency of T and PSA testing in prostate cancer in the real-world

By: Crawford E.D., Boldt-Houle D., Concepcion R., Atkinson S.

University of Colorado, Dept. of Urology, Aurora, United States of America,

Tolmar Pharmaceuticals, Inc., Dept. of Medical Affairs, Lincolnshire, United States of America,

Integra Connect, Dept. of Urologic Clinical, West Palm Beach, United States of America

Aims and objectives of this presentation
904

Switching from GnRH agonists to antagonists for castration-resistant prostate cancer as a second-line hormonal therapy: A multicenter prospective study

By: Sugimura R., Kawahara T., Yokomizo Y., Ohtake S., Kuroda S., Taku M., Ito H., Izumi K., Miyoshi Y., Yao M., Miyamoto H., Uemura H.

Yokohama City University Medical Center, Dept. of Urology and Renal Transplantation, Yokohama, Japan,

Yokohama City University Graduate School of Medicine, Dept. of Urology, Yokohama, Japan,

University of Rochester, Dept. of Surgical Pathology and Laboratory Medicine, Rochester, United States of America

Aims and objectives of this presentation
905
### Aims and objectives of this presentation

905

| 13:38 - 13:45 | **State-of-the-art lecture** *The advances in the treatment of CRPC*  
| R.J. Van Soest, Rotterdam (NL) |